Diabetes Treatment With Glucobay in Combination With Sulfonylurea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01613105
Recruitment Status : Completed
First Posted : June 6, 2012
Last Update Posted : June 26, 2013
Information provided by:

June 4, 2012
June 6, 2012
June 26, 2013
April 2008
December 2008   (Final data collection date for primary outcome measure)
  • Data collection on body weight [ Time Frame: 16 weeks ]
  • Data collection on blood glucose [ Time Frame: 16 weeks ]
  • Data collection on Hba1c [ Time Frame: 16 weeks ]
  • Data collection on pre treatment concomitant diseases [ Time Frame: 16 weeks ]
Same as current
Complete list of historical versions of study NCT01613105 on Archive Site
Safety variables will be summarized using descriptive statistics based on adverse events collection [ Time Frame: 16 weeks ]
Same as current
Not Provided
Not Provided
Diabetes Treatment With Glucobay in Combination With Sulfonylurea
Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Sulfonylurea Under Daily Life Treatment Conditions
In this prospective, non interventional, observational Post Marketing Survelliance study data are obtained on the efficacy, safety and tolerability of Glucobay treatment on top of sulfonylurea under daily life treatment conditions.Specifically investigated is the influence of Glucobay on Post Prandial Blood Glucose and HbA1c as well as on pateint's weight when added to an already existing sulfonylurea therapy.The study is planned to carried out in 25000 - 30000 patients from 200 trial sites in India.The Post Marketing Survelliance study will be performed with commercially available medication prescribed within regular practice of the physician. No other examination will be performed than would be done without Post Marketing Survelliance study.
Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Type 2 diabetes
Type 2 Diabetes Mellitus
Drug: Acarbose (Precose/Glucobay, BAYG5421)
Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
Group 1
Intervention: Drug: Acarbose (Precose/Glucobay, BAYG5421)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patient with type 2 diabetes with one of the following treatment ongoing : 1) Sulfonylurea 2) Sulfonylurea + OHA. In such patients, if investigator feels that addition of acarbose would be benficial for the patients

Exclusion Criteria:

  • According to local product information
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
GB0712IN ( Other Identifier: company internal )
Not Provided
Not Provided
Medical Director, Bayer Pharmaceuticals Pvt Ltd
Not Provided
Study Director: Bayer Study Director Bayer
June 2013